Skip to main content

Site notifications

A. Menarini Australia Pty Ltd

Regulatory activities for this sponsor.

Sponsor content

2 result(s) found, displaying 1 to 2
  • Orserdu monotherapy is indicated for the treatment of postmenopausal women and men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation.
  • Australian Public Assessment Report for Fentanyl citrate